Article
Inverse association of plasma level of high-density lipoprotein cholesterol with intracerebral hemorrhage.
Hypertension Division, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
The Journal of Lipid Research (impact factor:
5.56).
06/2011;
52(9):1747-54.
DOI:10.1194/jlr.P008755
pp.1747-54
Source: PubMed
- Citations (1)
-
Cited In (0)
-
Article: Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
[show abstract] [hide abstract]
ABSTRACT: To explore the relative contributions of baseline systolic blood pressure (SBP) and diastolic blood pressure (DBP) and lipoproteins on the risk of recurrent stroke or first major cardiovascular event (MCVE) and their potential impact on the benefit of statin treatment. The SPARCL trial randomized 4731 patients with recent stroke or transient ischemic attack (TIA) and no known coronary heart disease and LDL-C between 100 and 190 mg/dL to either atorvastatin 80 mg/d or placebo. Baseline assessment included SBP, DBP and measurements of low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C), and triglyceride levels. After 4.9 years of follow-up, there were 575 primary end points (fatal and nonfatal stroke), including 491 ischemic strokes, and 740 MCVEs (stroke plus myocardial infarction and vascular death). Cox regression models analysis showed a trend (P>0.05 and P<0.10) for higher SBP but not DBP to be associated with an outcome stroke with only SBP associated with MCVE. Only baseline low HDL-C was associated with an outcome stroke. Baseline HDL-C, triglycerides, and LDL/HDL ratio were each associated with MCVEs. There were no interactions between any of these baseline variables and the effect of treatment on outcome strokes. In patients with recent stroke or TIA and no coronary heart disease, only lower baseline HDL-C predicted the risk of recurrent stroke with HDL-C, triglycerides, and LDL/HDL ratio associated with MCVE. Atorvastatin treatment was similarly effective regardless of baseline lipoprotein levels.Atherosclerosis 09/2008; 204(2):515-20. · 3.79 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
95% confidence intervals
computed tomography
conventional cardiovascular risk factors
corresponding controls
detrimental effects
enzymatic methods
HDL cholesterol
HDL-C
HDL-C levels
intracerebral hemorrhage
lean participants
low plasma HDL-C
medical history
multivariable logistic regression model
odds ratios
participants
plasma cholesterol
Plasma HDL-C
plasma levels
third tertile